In addition, it has been reported that the BAFF-neutralizing monoclonal antibody Sandy-2 inhibits hepatic B2 cell responses and improves established NASH in a mouse model (83). Here, TNFSF13B is linked to metabolic dysfunction-associated steatohepatitis.